Deep Dive: Page 8
Industry insights from our journalists
-
5 trends shaping Alzheimer's drug development
Almost all Alzheimer’s drugs have failed. But pharma continues to invest millions in hopes of finding a hit, motivated by market opportunity and armed with lessons learned.
Ned Pagliarulo • July 17, 2017 -
What do we know about the amyloid theory for Alzheimer's?
A growing knowledge of the science behind the disease is allowing researchers to better test potential therapies.
Jacob Bell • July 17, 2017 -
Alzheimer's drug developers still hoping for a homer
The unmet need presented by the ever-growing patient population coupled with better science has the Alzheimer's disease pipeline filling up.
Malorye Allison Branca • July 17, 2017 -
A head above the rest? Drugmakers face off in migraine market
CGRP inhibitors could represent a step-change in the treatment of migraine — and potentially rake in billions of dollars in future sales for the four drugmakers developing them.
Ned Pagliarulo • June 30, 2017 -
FDA targets regulatory 'gaming' to boost generic competition
While the FDA has no direct role in drug pricing, agency head Scott Gottlieb hopes his planned actions could help address rising costs — at least in part.
Ned Pagliarulo • June 21, 2017 -
How Merck hopes to win in I/O combos: Q&A with Roy Baynes
Combinations are pegged as the next step forward in immuno-oncology. Speaking with BioPharma Dive at ASCO, Merck's Roy Baynes cautioned how little is known about the best pairing and explained why monotherapy remains relevant.
Ned Pagliarulo • June 14, 2017 -
Gene therapy by the numbers
In a field shaped by small patient populations and eye-popping cost considerations, understanding gene therapy's promise and challenges comes down, in part, to the numbers.
Ned Pagliarulo • June 12, 2017 -
Alternative pricing models a fantasy for gene therapies?
With an approval of Spark Therapeutics' gene therapy for a rare eye disease rapidly approaching, new questions about pricing are being raised.
Lisa LaMotta • June 12, 2017 -
5 Trends affecting gene therapy development
A pricing conundrum and ethical decisions are clouding an already hazy path to market for many gene therapy drugs and providers.
Jacob Bell • June 12, 2017 -
Industry Pulse: R&D spending in charts
Biopharmas are always on the hunt for ever-elusive innovations, but some are better at allocating investment than others. Here are five charts showing how the industry spends on R&D.
Ned Pagliarulo • May 30, 2017 -
Industry Pulse: Aging blockbusters tax bottom lines
A number of pharmas face declining sales and tougher competition to once-dominant brands. Here are eight charts showing which companies are most at risk.
Ned Pagliarulo • May 26, 2017 -
Consolidation in the CRO space a plus for biopharma
A recent spate of mergers between contract research and development organizations could spell greater efficiencies for mid-to-small pharmas in particular.
Barbara Boughton • May 24, 2017 -
Can value-based deals work if patients don't take the drug?
Drugmakers and payers are experimenting with how to align a drug's price with its value. Ensuring patient adherence is the first step to making sure the innovative deals get off the ground.
Ned Pagliarulo • May 15, 2017 -
Solutions to clinical trial adherence remain elusive
Making sure patients take their medications is crucial to clinical trial success, but exactly how to do that remains a daunting task for investigators.
Jacob Bell • May 15, 2017 -
Cancer immunotherapy works, but how to find which patients will benefit?
Bristol-Myers Squibb has paired up with Foundation Medicine to explore new ways of identifying patients most likely to respond to immuno-oncology drugs like Opdivo.
Ned Pagliarulo • April 25, 2017 -
Cancer combos key to AstraZeneca success, but rivals have long lead
Slowed by patent expiries, the British pharma hopes its pairing of durvalumab and tremelimumab will enable it to catch immuno-oncology leaders like Merck and Bristol-Myers.
Ned Pagliarulo • April 11, 2017 -
5 trends shaping rare disease drug development
Sales of orphan drugs have grown rapidly, prompting drugmakers to invest in rare diseases. But with that growth has come new scrutiny.
Ned Pagliarulo • April 10, 2017 -
The orphan drug dilemma: How to price for a tiny market
Despite small patient populations and historically high prices, the pricing model for rare disease drugs has reached a turning point, prompting companies and insurers to push for new innovative models.
Lisa LaMotta • April 10, 2017 -
Clinical trial enrollment gets harder as patient populations shrink
It can be a long shot to find patients for some rare disease clinical trials. Recruiting challenges, however, often make those odds even smaller.
Jacob Bell • April 10, 2017 -
AACR recap: IDOs under the microscope
Combination immunotherapy continued to draw attention at AACR. Elsewhere, survival data on several checkpoint inhibitors hinted at some long-term benefit.
Ned Pagliarulo • April 5, 2017 -
Investors have high expectations for cannabinoids
The pipeline is moving forward for cannabis-mimicking pharmaceuticals as investors' interest grows and new clinical data spark approval hopes.
Jacob Bell • March 13, 2017 -
How pharma is using mobile to call on patients
Companies like mProve Health are using mobile platforms to help pharma recruit and engage patients throughout the clinical trial process.
Lisa LaMotta • March 6, 2017 -
Changes to MYSTIC could set AstraZeneca up for success
The British pharma is attempting to catch immuno-oncology leaders Bristol-Myers and Merck by adapting the trial to boost durvalumab's chance of competing.
Ned Pagliarulo • March 6, 2017 -
How DTC got things moving for Linzess
The biotech has transitioned through three iterations of its DTC campaign for Linzess in as many years, despite each one being successful.
Lisa LaMotta • March 1, 2017 -
5 trends being impacted by biomarkers
The role of biomarkers in immuno-oncology and other cancer treatments is becoming increasingly important and is driving investment into multiple industries, including liquid biopsies and diagnostics.
Ned Pagliarulo and Lisa LaMotta • Feb. 13, 2017
Previous
